A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.
Information source: NIH AIDS Clinical Trials Information Service
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Meningitis, Cryptococcal; HIV Infections
Intervention: Flucytosine (Drug); Fluconazole (Drug)
Phase: N/A
Status: Completed
Sponsored by: Pfizer
Summary
To evaluate and estimate the safety and efficacy of the combination of fluconazole and
flucytosine as treatment for acute cryptococcal meningitis in patients with AIDS.
Fluconazole and flucytosine have different mechanisms of action. Since fluconazole has not
been associated with hematologic suppression and does not produce renal impairment that can
result in higher serum flucytosine levels, this combination may be better tolerated than is
amphotericin B plus flucytosine.
Clinical Details
Official title: A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.
Study design: Treatment, Randomized, Safety Study
Detailed description:
Fluconazole and flucytosine have different mechanisms of action. Since fluconazole has not
been associated with hematologic suppression and does not produce renal impairment that can
result in higher serum flucytosine levels, this combination may be better tolerated than is
amphotericin B plus flucytosine.
Patients in each cohort receive a lower dose of fluconazole alone or in combination with
flucytosine, or a higher dose of fluconazole alone. Doses in subsequent cohorts are escalated
if safety data in the previous cohort is satisfactory. Patients are evaluated weekly for the
first 4 weeks and every 2 weeks thereafter. Therapy continues until 8 weeks after the CSF
becomes culture negative, up to a maximum of 26 weeks.
Eligibility
Minimum age: 13 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria
Concurrent Medication:
Allowed:
- Antiviral therapy (AZT, DHPG).
- Prophylaxis for Pneumocystis carinii pneumonia.
- Treatment for intercurrent opportunistic infection.
Concurrent Treatment:
Allowed:
- Radiation therapy for mucocutaneous Kaposi's sarcoma.
Patients must have:
- AIDS.
- Evidence of Cryptococcal neoformans in culture or lumbar CSF OR clinical and CSF
findings compatible with cryptococcal meningitis.
- No evidence of acute or chronic meningitis of any etiology other than cryptococcosis.
- Life expectancy of at least 2 weeks.
Prior Medication:
Allowed:
- Prior antiviral therapy (AZT, DHPG).
- Prophylaxis for Pneumocystis carinii pneumonia.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Relapsing on maintenance triazole therapy for cryptococcal meningitis.
- Unable to take oral medication.
Concurrent Medication:
Excluded:
- Concomitant use of any antifungal agent other than study drug.
Patients with the following prior conditions are excluded:
History of allergy to or intolerance of imidazoles, azoles, or flucytosine.
Prior Medication:
Excluded:
- More than 1 mg/kg amphotericin B.
- Systemic antifungal agents within 7 days prior to study entry.
Locations and Contacts
UCI Med Ctr, Orange, California 92668, United States
Los Angeles County - USC Med Ctr, Los Angeles, California 90033, United States
UCSD Med Ctr - Owen Clinic, San Diego, California 921038681, United States
Additional Information
Related publications: Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, Bauer M, Tilles JG, McCutchan JA, Leedom JM. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994 Oct;19(4):741-5.
Last updated: June 23, 2005
|
